XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF LOSS - USD ($)
shares in Thousands
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating expenses:    
Research and development expenses $ 6,991,000 $ 3,852,000
Selling, general and administrative expenses 21,635,000 11,012,000
Restructuring income 0 (53,000)
Total operating expense 28,626,000 14,811,000
Operating loss (28,626,000) (14,811,000)
Investment and other (expense) income, net (137,000) 610,000
Interest expense (2,017,000) (1,929,000)
Gain from release of certain liabilities 33,000 78,000
Loss before income taxes (30,747,000) (16,052,000)
Income tax benefit (4,323,000) (2,607,000)
Net loss $ (26,424,000) $ (13,445,000)
Net loss per share - basic (in dollars per share) $ (0.45) $ (0.23)
Net loss per share - diluted (in dollars per share) $ (0.45) $ (0.23)
Weighted average number of shares outstanding - basic (in shares) 58,824 58,443
Weighted average number of shares outstanding - diluted (in shares) 58,824 58,443